Two leading breast cancer experts debated the proposition that platinum-based or other additional systemic agents should be used in difficult-to-treat cases of high-risk triple-negative breast cancer.
In a review of axillary management, it was found that regional node irradiation is likely important in reducing distant metastasis in high-risk breast cancer.
With increasing maternal ages worldwide, patients undergoing breast cancer treatment while pregnant is becoming a more common experience in clinical oncology.
Breast density legislation is based on a misunderstanding of density’s association with cancer risk, and clinicians should focus not on density per se, but density residuals—the difference between a patient’s predicted and actual breast density.
Targeted axillary dissection improves axillary staging and pathologic evaluation of residual nodal involvement after chemotherapy in node-positive breast cancer.
On November 30, 2015, the US Food and Drug Administration (FDA) approved elotuzumab (Empliciti, Bristol-Myers Squibb) as a second-line treatment for multiple myeloma, in combination with two other agents.
Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.
Pregnancy might stimulate tumor growth among women diagnosed with gliomas, according to a single-institution retrospective review of cases.
Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.
Targeted MAPK-pathway inhibitor therapies appear to have reduced tumor sizes in four children’s inoperable astrocytomas—tumors that had progressed despite chemotherapy.